 |
|
|
| |
Switching to a Single-tablet Regimen of Bictegravir, Emtricitabine, and
Tenofovir Alafenamide (B/F/TAF) from Dolutegravir plus Either F/TAF or F/TDF
|
| |
| |
Reported by Jules Levin
Mexico City IAS 2019 July 21-24
Paul E. Sax1, Jürgen Rockstroh2, Anne F. Luetkemeyer3, Yazdan Yasdanpanah4,
Douglas Ward5, Benoit Trottier6, Armin Rieger7, Hui Liu8, Rima Acosta8, Sean E. Collins8, Diana Brainard8, Hal Martin8 on behalf of the 380-4030 Investigators
1Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, USA; 2University Hospital Bonn, Bonn, Germany; 3University of California San Francisco, California, USA; 4Hopital Bichat Claude Bernard, Paris, France; 5Dupont Circle Physicians Group, Washington DC, USA; 6Clinique de Medecine Urbaine du Quartier Latin, Montreal, Quebec, Canada; 7University of Vienna Medical School, Vienna, Austria; 8Gilead Sciences, Inc., Foster City, CA, US
|
| |
|
|
|
|
|
